[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525280":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":81,"centralContacts":85,"locations":89,"responsibleParty":253,"collaborators":46,"id":255,"slug":256,"hasResults":257,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":46,"eligibilityCriteria":261,"healthyVolunteers":257,"sex":262,"minAge":263,"maxAge":46,"enrollmentInfo":264,"targetDuration":46,"studyType":267,"phases":268,"briefSummary":271,"conditions":272,"keywords":280,"overallStatus":92,"whyStopped":46,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},{"fullName":5,"class":6},"Indapta Therapeutics, INC.","INDUSTRY",[8,17,21,25,30,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1: Single Agent IDP-023 - Single Dose","EXPERIMENTAL","NHL or MM patient treated with a single dose of IDP-023 monotherapy",[13,14,15,16],"Drug: IDP-023","Drug: Cyclophosphamide","Drug: Fludarabine","Drug: Mesna",{"label":18,"type":10,"description":19,"interventionNames":20},"Phase 1: Single Agent IDP-023 - Multiple Doses","NHL and MM patients treated with multiple doses of IDP-023 monotherapy",[13,14,15,16],{"label":22,"type":10,"description":19,"interventionNames":23},"Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",[13,24,14,15,16],"Drug: Interleukin-2",{"label":26,"type":10,"description":27,"interventionNames":28},"Phase 2: Combination IDP-023 plus rituximab","NHL patients treated with multiple doses of IDP-023 in combination with rituximab",[13,29,24,14,15,16],"Drug: Rituximab",{"label":31,"type":10,"description":32,"interventionNames":33},"Phase 2: Combination IDP-023 plus daratumumab","MM patients treated with multiple doses of IDP-023 in combination with daratumumab",[13,34,24,14,15,16],"Drug: Daratumumab",{"label":36,"type":10,"description":37,"interventionNames":38},"Phase 2: Combination IDP-023 plus isatuximab","MM patients treated with multiple doses of IDP-023 in combination with isatuximab",[13,24,14,15,16,39],"Drug: Isatuximab",[41,47,53,59,65,69,72,76],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"DRUG","IDP-023","NK cell therapy",[18,22,9,31,36,26],null,{"type":42,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"Rituximab","Anti-CD20 antibody therapy",[26],[52],"Rituxan",{"type":42,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"Daratumumab","Anti-CD38 antibody therapy",[31],[58],"Darzalex",{"type":42,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"Interleukin-2","Immune cytokine",[22,31,36,26],[64],"Proleukin",{"type":42,"name":66,"description":67,"armGroupLabels":68,"otherNames":46},"Cyclophosphamide","Lymphodepleting chemotherapy",[18,22,9,31,36,26],{"type":42,"name":70,"description":67,"armGroupLabels":71,"otherNames":46},"Fludarabine",[18,22,9,31,36,26],{"type":42,"name":73,"description":74,"armGroupLabels":75,"otherNames":46},"Mesna","Chemoprotectant",[18,22,9,31,36,26],{"type":42,"name":77,"description":55,"armGroupLabels":78,"otherNames":79},"Isatuximab",[36],[80],"Sarclisa",[82],{"name":83,"affiliation":5,"role":84},"Indapta Therapeutics, Inc.","STUDY_DIRECTOR",[86],{"name":83,"role":87,"phone":46,"phoneExt":46,"email":88},"CONTACT","TRIALS@INDAPTA.COM",[90,109,120,130,145,154,169,183,193,208,223,238],{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"Valkyrie Clinical Trials","RECRUITING","Los Angeles","California","90670","United States","US",{"type":99,"coordinates":100},"Point",[101,102],-118.24368,34.05223,{"lat":102,"lon":101},[105],{"name":106,"role":87,"phone":107,"phoneExt":46,"email":108},"Myo Zaw","626-632-1963","myo.zaw@vctcare.com",{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":96,"countryCode":97,"cosmosGeoPoint":115,"geoPoint":119,"contacts":46},"Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center","WITHDRAWN","Lake Mary","Florida","32746",{"type":99,"coordinates":116},[117,118],-81.31784,28.75888,{"lat":118,"lon":117},{"facility":121,"status":92,"city":122,"state":123,"zip":124,"country":96,"countryCode":97,"cosmosGeoPoint":125,"geoPoint":129,"contacts":46},"Emory University Hospital","Atlanta","Georgia","30322",{"type":99,"coordinates":126},[127,128],-84.38798,33.749,{"lat":128,"lon":127},{"facility":131,"status":92,"city":132,"state":133,"zip":134,"country":96,"countryCode":97,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":99,"coordinates":136},[137,138],-93.26384,44.97997,{"lat":138,"lon":137},[141],{"name":142,"role":87,"phone":143,"phoneExt":46,"email":144},"Kayla Wagenmann, MN, RN, PHN","612-624-2342","wage0074@umn.edu",{"facility":146,"status":111,"city":147,"state":147,"zip":148,"country":96,"countryCode":97,"cosmosGeoPoint":149,"geoPoint":153,"contacts":46},"NYP\u002FWeill Cornell Medical Center","New York","10065",{"type":99,"coordinates":150},[151,152],-74.00597,40.71427,{"lat":152,"lon":151},{"facility":155,"status":92,"city":156,"state":157,"zip":158,"country":96,"countryCode":97,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Atrium Health Wake Forest Baptist","Winston-Salem","North Carolina","27157",{"type":99,"coordinates":160},[161,162],-80.24422,36.09986,{"lat":162,"lon":161},[165],{"name":166,"role":87,"phone":167,"phoneExt":46,"email":168},"Catalina Gonzalez-Pinzon","336-716-2957","cagonzal@wakehealth.edu",{"facility":170,"status":92,"city":171,"state":172,"zip":173,"country":96,"countryCode":97,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"University Hospitals Cleveland","Cleveland","Ohio","44106",{"type":99,"coordinates":175},[176,177],-81.69541,41.4995,{"lat":177,"lon":176},[180],{"name":181,"role":87,"phone":182,"phoneExt":46,"email":46},"UH Seidman Cancer Center Cancer Information Service Line","844-885-9659",{"facility":184,"status":111,"city":185,"state":186,"zip":187,"country":96,"countryCode":97,"cosmosGeoPoint":188,"geoPoint":192,"contacts":46},"Providence Cancer Institute Franz Clinic","Portland","Oregon","97213",{"type":99,"coordinates":189},[190,191],-122.67621,45.52345,{"lat":191,"lon":190},{"facility":194,"status":92,"city":195,"state":196,"zip":197,"country":96,"countryCode":97,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Rhode Island Hospital","Providence","Rhode Island","02903",{"type":99,"coordinates":199},[200,201],-71.41283,41.82399,{"lat":201,"lon":200},[204],{"name":205,"role":87,"phone":206,"phoneExt":46,"email":207},"Stephen Donnelly","401-444-4822","SDonnelly1@Lifespan.org",{"facility":209,"status":92,"city":210,"state":211,"zip":212,"country":96,"countryCode":97,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":99,"coordinates":214},[215,216],-86.78444,36.16589,{"lat":216,"lon":215},[219],{"name":220,"role":87,"phone":221,"phoneExt":46,"email":222},"Briana Smith","615-329-7449","briana.smith@scri.com",{"facility":224,"status":92,"city":225,"state":226,"zip":227,"country":96,"countryCode":97,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":99,"coordinates":229},[230,231],-95.36327,29.76328,{"lat":231,"lon":230},[234],{"name":235,"role":87,"phone":236,"phoneExt":46,"email":237},"Christy Allen","281-455-0250","callen6@mdanderson.org",{"facility":239,"status":92,"city":240,"state":241,"zip":242,"country":96,"countryCode":97,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"NEXT Oncology Virginia","Fairfax","Virginia","22031",{"type":99,"coordinates":244},[245,246],-77.30637,38.84622,{"lat":246,"lon":245},[249],{"name":250,"role":87,"phone":251,"phoneExt":46,"email":252},"Blake Patterson","703-783-4505","bpatterson@nextoncology.com",{"type":254,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100525280","phase-1-idp-023-as-a-single-agent-and-in-combination-with-antibody-therapies-in-patients-with-advanced-hematologic-cancers-100525280",false,"NCT06119685","IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Phase 1\u002F2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Key Inclusion Criteria:\n\n* For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and\u002For refractory (R\u002FR) disease after ≥ 3 prior lines of therapy.\n* For NHL patients: R\u002FR disease and failed ≥ 2 lines of systemic chemotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of greater than 12 weeks per the Investigator.\n\nKey Exclusion Criteria:\n\n* Impaired cardiac function or history of clinical significant cardiac disease.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.","ALL","18 Years",{"count":265,"type":266},128,"ESTIMATED","INTERVENTIONAL",[269,270],"PHASE1","PHASE2","This is an open label, Phase 1\u002F2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.",[273,274,275,276,277,278,279],"NHL","Multiple Myeloma","Blood Cancer","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma",[281],"Advanced Hematologic Cancers","2025-05-30",{"date":284,"type":285},"2025-06-03","ACTUAL",{"date":287,"type":285},"2023-10-25",{"date":289,"type":266},"2029-12-31",{"name":5,"class":6},12]